share_log

朝聚眼科(02219)发布2023年度业绩,股东应占溢利2.29亿元,同比增长21.9%

Chaoju Ophthalmology (02219) announced its 2023 annual results. Shareholders should account for profit of 229 million yuan, an increase of 21.9% over the previous year

Zhitong Finance ·  Mar 26 09:03

Chaoju Ophthalmology (02219) announced results for the year ended December 31, 2023, with revenue of 1,369.5 billion...

According to Zhitong Finance App News, Chaoju Ophthalmology (02219) announced results for the year ended December 31, 2023, with revenue of $1,369.5 million (RMB, same below), up 38.3% year on year; profit attributable to parent company owners of $229 million, up 21.9% year on year; basic profit of $0.33 per share, proposed final dividend of HK$0.2208 per share and special dividend of HK$0.0767 per share.

The Group's revenue increased 38.3% year over year, mainly due to the recovery in demand for ophthalmology services, the Group's ability to receive increased patient visits, industry recovery, and improvements in China's post-COVID-19 economic environment.

As of December 31, 2023, the Group operated a network of 31 ophthalmology hospitals and 29 optometry centers, spanning a total of seven provinces and autonomous regions in China. Ophthalmology hospitals specialize in ophthalmology services, while optometry centers provide a range of optometry products and services to meet the various needs of customers.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment